A NOVEL FLOW SYSTEM UTILIZING AN EXPLANTED PORCINE HEART TO DETERMINE THE EFFICACY OF CAVAL VALVE IMPLANTATION by KARTHIC ANBALAKAN
A NOVEL FLOW SYSTEM UTILIZING AN EXPLANTED PORCINE 











A THESIS SUBMITTED  
FOR THE DEGREE OF MASTER OF ENGINEERING 
 
DEPARTMENT OF BIOMEDICAL ENGINEERING 





I hereby declare that the thesis is my original work and it has been written by me in 
its entirety. I have duly acknowledged all the sources of information which have 
been used in the thesis. 
 












Dr Leo Hwa Liang, Dr Yap Choon Hwai, Tan Guo Dong Sean, Munirah Ismail and Chan Zhi 




Special thanks to 








Author: Karthic Anbalakan 
Student ID: A0086381Y 




TABLE OF CONTENTS 
Abstract ........................................................................................................................................... iii 
List of Tables .................................................................................................................................... v 
List of Figures .................................................................................................................................. vi 
List of Abbreviations ........................................................................................................................ x 
Chapter 1: Introduction .................................................................................................................. 1 
1.1 Hypothesis ............................................................................................................................. 2 
1.2 Aim of Study .......................................................................................................................... 2 
1.3 Thesis Organization ............................................................................................................... 3 
Chapter 2: Background ................................................................................................................... 4 
2.1 Tricuspid Valve ...................................................................................................................... 4 
2.2 Tricuspid Regurgitation ......................................................................................................... 6 
2.2.1 Pathophysiology of Functional Tricuspid Regurgitation................................................. 6 
2.2.1.1 Geometric Changes of Functional Tricuspid Regurgitation .................................... 9 
2.2.1.2 Progression of Functional Tricuspid Regurgitation ............................................... 10 
2.3 Current Treatment Methods ............................................................................................... 12 
2.3.1 Surgical Decision Making .............................................................................................. 12 
2.3.2 Tricuspid Valve Repair .................................................................................................. 14 
2.3.3 Tricuspid Valve Replacement ....................................................................................... 16 
2.3.3.1 Mechanical Heart Valves ...................................................................................... 17 
2.3.3.2 Bioprosthetic Valves ............................................................................................. 21 
2.3.3.3 Limitation of Tricuspid Replacement .................................................................... 22 
2.4 Novel Therapeutic Concepts ............................................................................................... 23 
 ii 
 
2.4.1 Mitralign System ........................................................................................................... 24 
2.4.2 TriCinch Device ............................................................................................................. 25 
2.5 Caval Valve Implantation .................................................................................................... 26 
2.5.1 Motivation for study ..................................................................................................... 26 
2.5.2 The concept of Caval Valve Implantation ..................................................................... 26 
2.6 Imaging and Flow Systems .................................................................................................. 30 
Chapter 3: Methodology ............................................................................................................... 33 
3.1 In-Vitro Flow Loop Set-Up ................................................................................................... 33 
3.2 Explanted Porcine Heart...................................................................................................... 35 
3.3 Caval Valves ......................................................................................................................... 39 
3.4 Echocardiographic Investigation ......................................................................................... 40 
3.4.1 Posterior 2-Chamber Long Axis Apical View................................................................. 41 
3.4.1 Quantification ............................................................................................................... 42 
Chapter 4: Results ......................................................................................................................... 46 
4.1 Preliminary Echocardiographic Imaging .............................................................................. 46 
4.2 Cardiac Output .................................................................................................................... 50 
4.3 Jugular Venous Pressure Profiles ........................................................................................ 51 
4.4 Echocardiographic Investigation ......................................................................................... 54 
Chapter 5: Discussion .................................................................................................................... 58 
Chapter 6: Conclusion ................................................................................................................... 64 






Tricuspid regurgitation (TR) is a neglected entity and often occurs secondary to left sided heart 
disease. For that reason TR is treated concomitantly with left sided heart diseases, like mitral 
regurgitation, since a second surgery carries too great a risk. In addition, the treatment methods 
for TR, which include repair and replacement, are open surgical procedures which also carry a 
high operative mortality. Therefore, TR is often left untreated in patients where the risks 
outweighed the benefits. 
To exacerbate this further, TR was found to be progressive and could potentially worsen in 2 
grades within 5 years. This leads to several other comorbidities which include, right heart 
congestive failure, hepatosplenomegaly, peripheral edema and ascites. Severe tricuspid 
regurgitation (STR) is associated to a 50% mortality rate at 5 year follow up, which highlights 
the importance of a potentially new therapeutic procedure that could enable the treatment of 
STR. 
To address this, a new percutaneous transcatheter technique known as Caval Valve Implantation 
(CAVI) was introduced. It involves the heterotopic implantation of caval valves in the vena cava 
in the hopes of alleviating the detrimental effects of STR.  
In this study, the efficacy of this procedure is tested through the development of a novel flow 
system which utilizes an explanted porcine heart. The system is meant to be physiologically 




The results reported in this study allude to the efficacy of CAVI as a potential therapeutic 
technique; cardiac output was found to be 2.22 times greater after CAVI, the Jugular Venous 
Pressure (JVP) waveform was restored along with a significant decrease in the central venous 
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Tricuspid regurgitation (TR) has long been an underestimated entity. TR being secondary to 
several diseases, like mitral regurgitation (MR), has been assumed to improve when the primary 
disease is treated. This misconception has resulted in TR being neglected and often overlooked 
in both clinical and surgical settings.
[23]
  
Recently, various studies have demonstrated that in addition to TR being secondary to several 
diseases, it is also progressive, and it may in turn potentially cause the onset of other diseases.
[23, 
25, 60]




The current methods for treatment are either to repair the tricuspid valve (TV) or to replace it. 
However, these methods are only performed if the benefits outweigh the risks, noting also that 
TV repair or replacement is often done concomitantly with surgeries intended to treat the left 
sided heart disease (LHD), which only serves to exacerbate the risks of the surgery.
[23, 48]
 
Resulting in many patients left untreated.  
This elucidates the benefits of a transcatheter approach in treating TR, since a percutaneous 
valve replacement would carry much less risk when compared to an open surgical approach. 
However, no such transcatheter approach is yet clinically available.
[23, 48]
 Moreover, experiments 
aimed at testing the feasibility of this approach, have yet to address the problem of fixation of the 
prosthetic valve in the highly dynamic and plastic tricuspid annulus (TA).
[5, 7]
 




In this study, it is hypothesized that utilizing an explanted porcine heart within an in-vitro flow 
system would allow for a greater physiological representation; which could potentially serve as 
an intermediary step before animal studies and preclinical trials to determine the efficacy of 
Caval Valve Implantation (CAVI).  
1.2 Aim of Study 
Therefore, the objective in this study is to analyze the effects of percutaneous heterotopic 
implantation of heart valves in the vena cava – CAVI.  
1) The physiological representation of the in-vitro flow system would be assessed on its ability to 
reproduce results from previous studies involving CAVI. These studies have demonstrated that 
the heterotopic implantation of valves in the superior vena cava (SVC) and inferior vena cava 
(IVC) would alleviate the detrimental effects of STR; by reducing the central venous pressure 
and increasing the cardiac output. 
2) Following which, the efficacy of CAVI will be further explored with this in-vitro flow system, 
through quantitative flow, pressure and echocardiographic assessments. Additionally, the 
reduction in regurgitation is to be quantified through the determination of the effective 
regurgitant orifice area; thereby expanding on the previous study.  
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1.3 Thesis Organization 
The following chapter will provide background into the tricuspid valve and the disease, 
specifically focusing on the pathophysiology, geometric changes and progression of the disease; 
in a bid to highlight the severity of the disease as well as the need for new therapeutic 
interventions. It will also address the current treatment methods and the limitations of these 
methods so as to demonstrate how Caval Valve Implantation could potentially address these 
shortcomings.  
In chapter 3 the discussion will address how the in-vitro experimental set up was established. It 
will outline how the porcine heart was processed and prepared for the experimentation. The 
specifications of the caval valve will also be highlighted along with the equipment used – to 
extract the relevant results.  
Chapter 4 will encompass the results for the volumetric flow profile, pressure waveforms and the 
echocardiographic investigations. Subsequently, chapter 5 will review the results and address the 
inherent limitations of the study. 
Chapter 6 will explore potential improvements and future works pertaining to this study. It will 
also highlight why some previously explored ideas are not feasible in this in-vitro investigation.  
 




2.1 Tricuspid Valve 
The TV has a complex morphology that involves 3 leaflets in a non-planar, elliptical saddle 
shaped annulus. It comprises of four primary elements: the valve leaflets, the valve annulus, 
papillary muscles and the chordae tendineae. The largest of the leaflets is the anterior leaflet, 
followed by the posterior leaflet and the septal leaflet. The posterior leaflet extends from the 
posterior margin of the TA, from the septum to the infero-lateral wall, while the septal leaflet 




Figure 2-1: 3 dimensional transthoracic echocardiography (a) and intraoperative echocardiographic view (b) of 
the tricuspid valve. SL = septal leaflet, AL = anterior leaflet, and PL posterior leaflet. Image from [23] 
The TA is non-planar, with the highest point at the antero-septal portion and the lowest at the 
postero-septal portion, as seen in figure 2-2. The area of the TA ranges from 3.9    to 5.6   , 
with an approximate percentage change of 30% during the cardiac cycle.
[34]
 Although 
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identifiable, the ‘fibrous’ TA along the parietal attachment of the leaflets is difficult to define. In 




Figure 2-2: The tricuspid annulus has a complex geometry with the postero -septal portion being the lowest and 
the antero-septal portion being the highest. Image from [80] 
The chordae tendineae stem from each of the papillary muscles (usually three) and branch into 
several insertion areas on the leaflets. The marginal chordae refer to those which attach onto the 
tip of the free leaflet edge. These usually tend to be thinner than the basal chordae which attach 
onto the basal region close to the annulus. The marginal chordae help to keep the leaflets 
stationary while the basal chordae take on a more supportive role. The papillary muscles prevent 
the TV from prolapsing into the atrium during ventricular systole.
[85]
 
These four components work in tandem to ensure proper functioning of the TV. In a healthy 
heart, no flow is observed through the TV during systole, while a biphasic flow profile is 
observed during diastole. The first peak is called the ‘E wave’ and occurs due to ventricular 
relaxation. During isovolumic relaxation, the right atrial pressure exceeds that of the right 
ventricle causing the TV to open and the blood to flow through – passive ventricular filling. 
Following ventricular relaxation the atrium contracts, accelerating the blood into the ventricle 
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once more and accounting for the second peak called the ‘A wave’.[85] The flow profile of the 




2.2 Tricuspid Regurgitation 
TR is a complex valvular lesion in which the TV leaks – resulting in the retrograde flow of blood 
into the atrium, instead of the pulmonary artery, during systole. TR is characterized as either 
organic or functional. Organic TR is a result of structural abnormalities of the TV, which may 
either be acquired or congenital in nature. Organic TR accounts for 8-10% of all STR.  
Functional TR on the other hand, is due to the deformation of the TV apparatus – dilation and 
geometric changes to the TA – and accounts for more than 90% of all STR.[4, 58] TR can result 
from a number of comorbidities such as right ventricle (RV) enlargement due to left-sided heart 
valve disease, LV or RV dysfunction, pulmonic stenosis or regurgitation, pulmonary 
hypertension, and dilated cardiomyopathy.
[23]
 Table 1 illustrates a more comprehensive list of the 
aetiology for both functional and organic (structurally abnormal) TR.  
In this study, no distinction is made between organic and functional TR (with the exception 
2.2.1) since CAVI is a heterotopic implantation and does not address the native leaflets directly.  
2.2.1 Pathophysiology of Functional Tricuspid Regurgitation 
RV enlargement and dysfunction may be primary or secondary to LHD; which may lead to 
pulmonary hypertension. Functional TR that arises due to this ventricular deformation is often a 
result of valve tenting. In contrast, functional TR that occurs in the absence of pulmonary 
hypertension is predominantly due to annular enlargement, as seen in figure 2-3. This explains 
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why despite the association between pulmonary hypertension and TR, not all patients with 
pulmonary hypertension develop significant TR.
[4, 57, 81]
 This was further exemplified in an 
echocardiographic study, where mild TR was observed in 65% of patients with pulmonary artery 
pressures (PAPs) between 50 and 65 mmHg and only 46% in patients with PAPs above 
70mmHg 
[23, 58]
. This indicates that other factors such as atrial fibrillation, pacemaker leads, and 




Figure 2-3: Pathophysiology of Functional Tricuspid Regurgitation. Image from [4] 
TR results in chronic RV volume overload, which causes right sided congestive heart failure. 
Patients usually demonstrate signs of liver congestion, peripheral edema and ascites. When TR 
occurs secondary to LV dysfunction, patients may present with dyspnea, orthopnea and 





 Therefore the natural history of TR is poor, even more so 
with severe tricuspid regurgitation (STR) where the patients are highly symptomatic. 
In a study, Nath et al. 
[60]
 looked into the prognostic significance of TR in a group of 5223 
patients undergoing echocardiography. This revealed, at a 4 year follow up, that more that 70% 
of patients with mild or less TR were still alive while less than 50% of patients with STR 
survived. Moreover, despite pulmonary hypertension being one of the primary indicators for 
surgical intervention 
[8]
, TR is associated with higher mortality regardless of the presence of 
pulmonary hypertension.
[60]
 Similarly, while LV dysfunction is a well-established risk factor for 
early mortality in patients, STR is associated with worse survival regardless of LV ejection 
fraction; in both healthy individuals and in patients undergoing left heart valve surgery.
[10, 60]
  
Table 2-1: Aetiology of Tricuspid Regurgitation. Image from [4] 
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2.2.1.1 Geometric Changes of Functional Tricuspid Regurgitation  
The introduction of real time three-dimensional echocardiography (RT3DE) has provided new 
insights into the pathophysiological mechanisms of TR.
[3, 73]
 In TR, the leaflets of the TV fail to 
coapt due to the geometrical changes in the TA. The annulus tends to dilate in the anterior and 
posterior directions, causing it to assume a more circular shape as shown in figure 2-4. This is 
evidenced by the decrease in the medial-lateral/antero-posterior ratio from            
to            ,        .[80] Moreover, both the maximum and minimum TA areas were 
significantly larger in patients with TR.
[34]
 Annular dilation may become irreversible over time. 
This is observed in patients with chronic thromboembolic pulmonary hypertension, in whom 





Figure 2-4: A) The TV of a healthy heart viewed from the atrium. B) Dilation of TV in a heart with TR, viewed 
from the atrium. Image from [80] 
Furthermore, through RT3DE studies , TR has been shown to cause a decrease in the TA 
contraction, especially in severe cases, from 29.6% to 14.6%.
[34]
 In addition, annular flattening 
has also been observed in TR which results in the loss of the biomodal shape of the TA.
[80]
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2.2.1.2 Progression of Functional Tricuspid Regurgitation 
The development of functional TR is often illustrated in three stages, as seen in figure 2-5.
[26, 78]
 
The first stage is described as the initial annular dilation of the TV. At this stage, TR is still to be 
considered mild or moderate. In the stage that follows, the annular dilation increases thereby 
preventing the normal coaption of the tricuspid leaflets; causing the TR to become significant 
and RV to begin dilating. The final stage reflects the RV dilation and its subsequent dysfunction. 
This results in papillary muscle displacement and increased tethering forces leading to further 
leaflet malcoaption.
[23, 33]
 As the dilation of the RV increases, so does the RV diastolic pressure, 
which in turn causes further leftward septal displacement and LV compression. This would result 





Figure 2-5: Progression of TR in 3 phases. Image from [78] 
Similarly, other studies have also indicated that TR is a progressive disease and leaving it 
untreated, at the time of MV surgery, begets more regurgitation at follow-up.
[19, 23, 25]
 In one such 
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study, the progression of moderate to mild TR in 174 patients, undergoing isolated MV surgery, 
was analyzed. At a follow-up of 8.2 years TR had evolved into moderate to severe in 16% of the 
patients.
[53]
 Through multivariate analysis, uncorrected moderate TR, atrial fibrillation, and huge 
left atrium, were identified as statistically significant factors in predicting progression of TR after 
surgery.
[23]
 De Bonis et al. further demonstrated, that if the presence of moderate to severe TR at 
follow-up was considered together with the worsening of the TR by 2 grades, at a mean follow-
up of 1.8 years, the likelihood of progression of TR reaches 18.6%.
[19]
  
Furthermore, Dreyfus et al. 
[25]
 showed that TR worsened by more than 2 grades in 48% of 
patients undergoing isolated mitral valve (MV) repair and only 2 % in patients who were 
undergoing both MV and TV repair. Patients with moderate to severe TR, undergoing isolated 
MV annuloplasty, have been observed to have a significantly lower 5 year survival rate and 
possibility of being alive in the NYHA classes 1-2 as compared to those with mild or less TR.
[24]
  
These studies suggest that TR may not resolve after treating the primary LHD. Desai R.R et al. 
[21]
 concluded that in patients with both mitral valve disease and STR, isolated mitral valve repair 
improved TR and RV function; however this was incomplete and only temporary. However, 
reported that concomitant TV repair, conversely, eliminated STR and improved RV function, 
significantly reducing the likelihood of worsening TR and improved the survival rate.
[21]
  
The progressive nature of TR could potentially be due to further RV enlargement and 
dysfunction, resulting in increased annular dilation and papillary muscles displacement with 
leaflet tethering.
[19]
 This vicious cycle could elucidate the prognostic significance of untreated 
moderate to severe TR. Since persistent or worsening TR is associated with elevated pulmonary 
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artery pressures; which induces congestive hepatopathy with liver fibrosis, atrophy of 
hepatocytes, and potentially cirrhosis.
[23, 48]
 
Ultimately, the natural history of TR is unfavorable; considering it is a progressive disease and 
one that is often left untreated due to the high risk associated with the treatment procedures. 
Aside from it being secondary to LHD, persistent and worsening TR leads to increased 
pulmonary pressures and reduced cardiac output, which in turn leads to other comorbidities.
[48]
  
2.3 Current Treatment Methods 
Surgical repair and replacement are the only corrective therapies, currently available to treat TR, 
and they are associated with a high operative mortality of 22%.
[1, 48]
 Although transcatheter valve 
therapy is clinically available for the treatment of aortic, mitral and pulmonary valve diseases no 
similar method is yet available for TR.
[16, 27, 41, 83]
 Since a transcatheter technique is associated 
with fewer complications and lower mortality, it would be a great asset in treating TR. To this 
end, new therapeutic methods are being developed.
[78]
 
However, it is important to analyze the current surgical methods and their respective 
shortcomings to ensure the success of the newer therapies. Another concern is when should the 
repair/replacement of the TV be performed, in relation to surgery intended for the LHD?  
2.3.1 Surgical Decision Making  
TV repair is often done concomitantly with left sided heart surgery and the decision to perform 
repair is often left to the surgeon’s discretion.[10, 32] Pre-operative echocardiographic parameters 
and intraoperative findings have recently been gaining increasing importance for decision 
making. Aside from the severity of TR other factors such as annular diameter, have to also be 
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considered. This was observed in a study by Dreyfus et al. 
[25]
, where TV annuloplasty was only 
performed when the TA diameter was greater than twice the normal size (>70mm), regardless of 
severity of regurgitation. According to the ESC (European Society of Cardiology) guidelines, TV 
annuloplasty should only be considered in patients with moderate TR with a dilated annulus 
(>40mm from the AP-4CV) undergoing left sided valve surgery.
[58]
 
In a study by Chopra et al. 
[15]
, patients with non-severe TR were found with maximal diastolic 
tricuspid annular diameter that was within the normal range; implying that TR may occur 
without annular dilation and is not the sole criteria for surgical decision making. 
 The decision to perform TV annuloplasty could also be based on the preoperative 
echocardiographic systolic dimensions of the tricuspid annulus (sysTA). To this end, Calafiore et 
al. 
[11]
 determined the normal reference values by studying twenty healthy volunteers; median 
sysTA of 24mm and maximum sysTA of 28mm were established accordingly. TV annuloplasty 
was recommended for patients with moderate to severe TR and in those with mild TR if sysTA 
was found to be greater than 24mm. Patients with sysTA less than 24mm who underwent MV 
surgery without TV repair showed no worsening of TR at midterm. Whereas untreated patients 




Therefore, while the decision to treat the TV during left sided heart surgery is still ultimately left 
to the discretion of the surgeon, there are several preoperative echocardiographic parameters that 
could potentially aid in the discerning the appropriate course of treatment.  
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2.3.2 Tricuspid Valve Repair  
TV repair is usually prophylactic and is directed at reshaping the annulus through either suture or 
ring annuloplasty.
[23]
 This surgery is often directed at patients with lesser degrees of preoperative 
TR but have a dilated annulus. Suture annuloplasty methods aim to reduce the annular size by 
using a continuous suture to purse string the annulus.
[79]
 Some of the more common suture 
annuloplasty techniques are the Kay repair, De Vega Repair and the Clover Techniques.
[79]
  
The Kay repair method involves the bicuspidization of the TV. This is accomplished by plicating 
the annulus along the posterior leaflet thereby obliterating the leaflet when the sutures are tied. 
This creates a bicuspid valve, as seen in figure 2-6B.
[40]
 The De Vega annuloplasty on the other 
hand, involves plicating both the anterior and posterior leaflets; using a single suture around the 
TA while avoiding the atrioventricular node (figure 2-6C).
[22]
 Annuloplasty can also be achieved 
by suturing a support device like a pericardial strip or a semi-rigid/rigid prosthetic ring to 
permanently fix the annulus in the systolic position (figure 2-6D).
[12, 35]
  Another example of ring 
annuloplasty is the Edwards MC3 annuloplasty system 
[31]
, as seen in figure 2-7. The clover 
technique on the other hand, is often used to address the severe tethering and involves the 
suturing of the free edges of the tricuspid leaflets as seen in figure 2-6E.
[18]
 
In general, the survival curves based on the surgical techniques did not differ significantly across 
the studies.
[43, 55]
 However, several studies have demonstrated that ring annuloplasty is more 
durable than suture annuloplasty, and that it is associated with better event free survival in both a 
10 year
[63]
 and 15 year
[77]
 follow up. 




Figure 2-6: Kay Technique (Left): A: Tricuspid Valve bicuspidization is done by plicating the posterior the 
annulus along the posterior leaflet. B: The sutures are tied obliterating the posterior leaflet, converting the 
tricuspid valve into a bicuspid valve. Other techniques (Right): C: De Vega repair where a single suture is placed 
around the tricuspid annulus, avoiding the area of the atrioventricular node. The suture is tied completing the 
annuloplasty. D: Tricuspid annuloplasty with a rigid prosthetic ring. E: The clover technique: The middle parts of 
the free edges of the tricuspid annulus are sutured together. Image from [79]. 
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TV repair however, is still associated with a recurrence rate of 2.5% to 5.5% at a 1 year follow 
up.
[10, 11, 54]
 In addition, a study by Navia et al. 
[61]
 reported that flexible bands and pericardial 
strips used in ring annuloplasty are associated with a higher TR recurrence at a 5 year follow up. 
Similarly, McCarthy et al. 
[55]
 found that, at a 8 year follow up, rate of repair failure is 17%, 33% 
and 37% for ring annuloplasty, DeVega technique and pericardial strip annuloplasty, 
respectively.  
Therefore, TV repair continues to be a high risk procedure which is associated with recurrent 
TR. This further emphasizes the importance for a new potential percutaneous transcatheter 
technique to treat TR.  
2.3.3 Tricuspid Valve Replacement 
Patients who exhibit RV dysfunction with RV dilation would not benefit from TV repair – suture 
or ring annuloplasty – and would present a high risk of failure. These patients instead undergo 
curative surgery because TV annuloplasty will result in increased tethering of the anterior and 
posterior leaflets, since the annulus is displaced toward the septum.
[23]
 Therefore, in patients with 
RV dilation, surgical tethering will result in postoperative TR worsening rather than better leaflet 
coaption. Hence, the only option clinically available would then be TV replacement, which 
involves the insertion of a prosthetic valve within the annulus.
[23, 48]
  
The ideal heart valve for TV replacement should: produce minimal pressure drop, have small 
regurgitant volumes, minimize turbulence, reduce high shear stress and not create stagnation or 
flow separation within the flow field.
[85]
 Pressure drop across the valve determines the 
effectiveness of the prosthetic valve. A large drop in pressure would in turn demand a greater 
systolic pressure in order to drive circulation. Therefore, an effective prosthetic heart valve 
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would not cause too great a flow resistance and thereby minimize the pressure drop.
[72]
 Similarly, 
heart valves that induce regions of flow separations and stagnations are less than ideal. They are 
associated with increased likelihood of thrombus formation, tissue overgrowth and possible 
calcification.
[85]
 In addition, prosthetic valve designs may also cause high flow velocities, shear 
stress and excessive turbulence which could result in hemolysis of blood cells and lead to 
thromboembolic complications.
[36, 70]
 Therefore, factors such as flow velocities, flow fields and 
flow shear stress should be considered when optimizing a design for prosthetic valves. 
Moreover, since these factors are used to determine the ideal hemodynamic flow, they are also 
relevant in determining the effectiveness of various tricuspid valve repair strategies.  
2.3.3.1 Mechanical Heart Valves 
There were three main designs for the mechanical heart valves: Caged ball design, tilting disc 
and the bileaflet valve.
[85]
 While the caged ball heart valve had good reliability it was associated 
with very poor hemodynamic performance and as of 2007 the Starr-Edwards caged ball, the only 
caged ball design available, was discontinued by Edward Lifesciences.
[14]
 Therefore only the 
tilting disc and bileaflet mechanical heart valves will be discussed.   
Tilting Disc Valve 
The Medtronic-Hall mechanical valve is the most commonly used tilting disc valve. As 
suggested by the name, it has a major and a minor orifice which is divided by a tilting disc. Two 
nearly symmetrical flow profiles are observed from both the major and minor orifice.
[85]
 
However, the major orifice jet is larger and has a slightly higher velocity as compared to its 
minor counterpart, as seen in figure 2-8A.
[84]
 A region of retrograde flow occurs adjacent to the 
wall in the minor orifice at peak systole, 2mm from the wall, shown in figure 2-8. Moreover, a 
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region of flow separation forms next to the wall of the major orifice and flow stagnation is also 
observed immediately downstream from the minor orifice during the acceleration and 
deceleration phases.
[85]
 The tilting disc mechanical valve has a slightly smaller regurgitant 
volume when compared to the bileaflet mechanical heart valve. Moreover, the performance 
indexes (PIs), which is the ratio of the effective orifice area to the valve sewing area, ranges 
between 0.40 to 0.65.
[85]
 The PIs help to reflect how well a prosthetic valve design optimizes its 
total mounting area. 
Furthermore, leakage jets are often observed in the gap between the disc and the housing. While 
these jets might be useful in ‘washing’ of the gap region, they are also associated with high 
velocities and turbulent shear stresses. The maximum turbulent shear stress associated with the 
tilting disc design is between 1200 to 1500 dyne/   , as seen in figure 2-8. Even though this is 
below the hemolysis threshold of 4000 dyne/    for the Reynolds’s shear stress, the damage 
mechanism for hemolysis is a complicated process which is affected by the resident time of the 
blood cells in the affected environment.
[70, 85]
 Therefore, this could potentially still lead to 
thromboembolic complications. 
Bileaflet Mechanical Valve 
St. Jude Medical bileaflet mechanical valve is the most commonly used bileaflet valve and has 
two semicircular leaflets that divide the effective orifice area into 3 regions: 2 lateral regions and 
a central orifice. Most of the forward flow occurs in the 2 lateral orifices, as seen in figure 2-9.
[84]
 
Flow separation occurs adjacent to the flow channel wall where the flow separates from the 
orifice ring. Small regions of retrograde flow also occur next to the hinge mechanism of the 
valve. The maximum turbulent shear stress levels are found to be 3000 dyne/   , which is 
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within the threshold range. Although the bileaflet mechanical valve has a slightly larger 





Figure 2-8: Medtronic-Hall tilting disc valve flow profile  (A) Velocity proﬁle 15 mm downstream on the 
centerline across the major and minor oriﬁces (major oriﬁce to theright) at peak systole; (B) velocity proﬁles 13 
mm downstream in the major and minor oriﬁces at peak systole; (C) turbulent shearstress proﬁle 15 mm 
downstream on the centerline across the major and  minor oriﬁces at peak systole; (D) turbulent shear stress 
proﬁles 13 mm downstream in the major and minor oriﬁces at peak systole. Image from [84] 
Mechanical heart valve designs are optimized through laser doppler velocimetry and 
computational fluid dynamics. These studies are often aimed at improving the hinge design as 
well as at minimizing the likelihood of cavitation.
[28, 29, 50]
 Although CAVI involves a stented 
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valve (caval valve) that is to be deployed percutaneously, advances in the mechanical valve 
design might lend some insight into optimizing valve design specific to the process of CAVI.  
 
 
Figure 2-9: Flow profile of St. Jude Medical bileaflet valve (A) Velocity proﬁle 13 mm downstream on the 
centerline during peak systole; (B) velocity proﬁle 13 mm downstream across the central oriﬁce during peak 
systole; (C) turbulent shear stress proﬁle 13 mm downstream of the centerline oriﬁce during peak systole; (D) 
turbulent shear stress proﬁle 13 mm downstream across the central oriﬁce during peak systole . Image from [84] 
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2.3.3.2 Bioprosthetic Valves 
Bioprosthetic valves are usually composed of three biological leaflets made from porcine aortic 
valve leaflets or bovine pericardium. These tissues are extracted and treated with a 
gluteraldehyde solution before being sutured onto a metal or polymeric stent.
[85]
 Unlike their 
mechanical valve counterparts, bioprosthetic valves or tissue valves do not have any occlusion in 
their central orifice. These valves tend to produce high velocity jet-like forward flow profiles. 
The flow profiles also tend to be more evenly distributed as compared to the mechanical valves, 
as seen in figure 2-10. Although no flow separation is usually observed during the systolic 
period, flow stagnation occurs throughout systole at the annular region between the outflow 




Figure 2-10: Flow profile of Carpentier-Edwards pericardial valve (A) Velocity proﬁle 17 mm downstream on the 
centerline during peak systole; (B) turbulent shear stress proﬁle 17 mm downstream on the centerline during peak 
systole 
Chapter 2: Background  
22 
 
Generally, all tissue valves are mildly stenotic compared to the natural valve. This is due to the 
stent restriction to leaflet opening, construction of leaflets, stiffness of treated tissue and man-




In bioprosthetic valves, high turbulent shear stresses usually occur at the edge of the central jet 
and range between 1000 to 4500 dynes/   .[84] The flow profile of the Carpentier-Edwards 
pericardial valve at peak systole is shown in figure 2-10.
[85]
 
Mechanical or Bioprosthetic heart valve 
The choice between a mechanical valve and a bioprosthetic valve has been controversial topic. 
Some researchers have reported that mechanical valves are superior to bioprosthetic valves,
[39, 67]
 
while others have reported that bioprosthetic valves are in fact superior.
[13, 17, 56]
 However, in a 
more recent study, 
[30]
 the long term survival of patients was found to be similar regardless of 
prosthesis used. This was further supported by a meta-analysis of 11 studies conducted by 
Rizzoli et al.
[68]
 which reported no significant difference in early mortality, late survival or 
reoperations.     
2.3.3.3 Limitation of Tricuspid Replacement 
Although mechanical and bioprosthetic heart valves have their respective advantages and 
disadvantages, the inherent problems associated with heart valves have yet to be eliminated.
[85]
 
Thromboembolic complications, anticoagulant-related hemorrhage, tissue overgrowth and 
paravalvular leakage owing to healing effects are some of these problems.  
Chapter 2: Background  
23 
 
In fact, TV replacement is associated with high mortality rate and is only considered as a 
therapeutic option when TV repair is no longer viable. 
[64]
 In a study by Ratnatunga et al.
[66]
 the 
early mortality rate associated with tricuspid valve replacement was reported to be 22%. The 




Ultimately, the current treatment modalities of TV repair and replacement still carry too great an 
operative risk. This is reflected by the significant number of people with STR who are left 
untreated due to said risks.
[78]
 Therefore, a transcatheter approach would be ideal for treating 
patients with TR since it is associated with significantly lower mortality and complications. 
However, while transcatheter therapy has bolstered the therapeutic options for patients with 




Hence in this study, the efficacy of the heterotopic implantation of valves in the vena cava is 
investigated as a potential therapeutic solution to TR. 
2.4 Novel Therapeutic Concepts  
Even though percutaneous procedures are an ideal treatment modality for TR, there are still none 
that are clinically available. However, several novel percutaneous transcatheter based techniques 
are under evaluation and in preliminary clinical research trials.
[78]
 Despite the limitation in data 
and the preliminary nature of the current investigations, these ideas are worth exploring. 
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2.4.1 Mitralign System 
The Mitralign device (Mitralign, Inc. Tewsbury, USA) was initially intended to treat mitral 
regurgitation but has recently been used to treat TR as well.
[75]
 Mitralign system treats TR by 
performing a transcatheter bicuspidization of the TV through the transvenous jugular 
approach.
[74]
 A steerable catheter is inserted into the RV across the TV and positioned with 
echocardiographic imaging. Following which, a radiofrequency wire is advanced from the base 
of the leaflet and within the annulus and guided toward the right atrium; where it is positioned 
adjacent to the anteroposterior commissure. After the wire is through the annulus, a pledget 
delivery catheter is moved over the wire from the right atrium across the TV to the RV. This 
process is repeated opposite to the anteroposterior commissure. A dedicated plication lock device 
is then used to bring the pledgeted sutures together, plicating the annulus and converting it into a 




Figure 2-11: The Mitralign concept. (A)The pledget delivery catheter is advanced over the wire fro m the right 
atrium. (B) Plication of the annulus and reduction of its dimension. Image from [78] 
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2.4.2 TriCinch Device 
The TriCinch (4Tech Cardio, Galway, Ireland) device, as the name suggests, aims to reduce 
anteroseptal annular dimension and TR by cinching the TA. To achieve this, a steerable catheter 
is introduced in the femoral vein and advanced to the TA.
[45]
 The catheter is placed between the 
anteroposterior commissure and the mid anterior annulus. Following this, a corkscrew is 
implanted adjacent to the mid part of the anterior TA, as seen in figure 2-12. Right coronary 
artery angiography is performed to ensure no coronary damage. After the corkscrew is secured, 
the delivery system is extracted. A self-expandable Nitinol stent is then introduced over the wire 
and coupled to the implant. Tension is used to reshape the TV by cinching the annulus to 
increase leaflet coaption. Finally, a stent is deployed in the IVC to maintain the tension, as 




Figure 2-12: The TriCinch concept. (A) The corkscrew is implanted in the target zone. (B) The system is 
tensioned to reshape the annulus. The stent is deployed in the IVC to maintain the tension. Image from [78] 
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2.5 Caval Valve Implantation 
2.5.1 Motivation for study 
Like the Mitralign system and the TriCinich device, Caval Valve Implantation (CAVI) is also a 
new transcatheter therapeutic technique with limited data to support any evidence of its clinical 
efficacy. Therefore, this study aims to develop a physiologically representative in-vitro flow 
system that would be able to lend some insight into the efficacy of CAVI. 
This study focuses on CAVI over the Mitralign system and the TriCinich device due to their 
inherent limitations. The Mitralign system, while a promising technique which is based on a 
proven surgical background,
[35, 61, 78]
 is technically challenging and requires an advanced 3D 
echocardiography imaging system.
[78]
 The TriCinch device similarly, requires advanced imaging 
and is only applicable to patients who do not present with significant RV dysfunction.
[78]
 CAVI 
on the other hand, is technically very easy to perform and is not restricted by the same 
complexities as the other techniques.
[78]
 Therefore, it would be feasible for an in-vitro flow 
system, utilizing an explanted porcine heart, to be sufficiently physiologically representative to 
study CAVI. Furthermore, 2D color doppler echocardiography would be able to quantify the 
efficacy of CAVI within the proposed flow system. 
2.5.2 The concept of Caval Valve Implantation  
Boudjemline et al. 
[9]
 experimented with a catheter based approach to treat TR by implanting a 
double disc nitinol stent with a semilunar valve into the tricuspid annulus. While the technicality 
of the process was proven to be feasible, several shortcomings such as the lack of fixation of the 
self-expanding valve in the highly plastic TA were not resolved.
[9, 48]
 This was further supported 
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by a subsequent study, in which the authors claimed that percutaneous valve replacement for TR, 
by means of orthotopic valve implantation, proves to be extremely challenging with the currently 
available materials and methods.
[5, 48, 49]
 However, CAVI leverages on the benefits of a 
transcatheter approach whilst avoiding the problem of fixation faced by an orthotopic 
implantation; thereby alluding to its potential to be a new therapeutic procedure capable of 
treating STR, especially in patients considered to be inoperable. 
CAVI is described as the heterotopic implantation of caval valves into the SVC and IVC to 
reduce venous regurgitation and congestion; caused by STR,
[48, 49, 78]
 as seen in figure 2-13. For 
this reason it is said to ‘ventricularize’ the right atrium. By reducing the hepatic, abdominal and 
peripheral venous congestion, CAVI aims to ameliorate right heart failure.
[78]
 Since the 
implantation is at a low pressure site, patients would probably require lifelong anticoagulants. 
However, since TR is often found secondary to LHD, most patients would already be subjected 
to the same anticoagulant therapy.
[78]
 
The feasibility of this procedure was demonstrated by Lauten et al. 
[49]
 through experimental 
study in animals. In said study, a significant reduction of the v-wave and y-descent was reported 
in the IVC along with an increase in the cardiac output (CO); alleviating the deleterious effects 
of TR.
[48, 49]
 Moreover, strong fixation of the valves to the venous wall by fibrous covering 
implied that device migration would be highly improbable. CAVI however, does not address the 
damaged native tricuspid valve, therefore atrial overloading and increased atrial pressures within 
the right atrium were observed in this study, as seen in table 2. A subsequent study was done in a 
patient who was deemed inoperable due to previous open-heart surgeries and significant 
comorbidities. CAVI was performed as a ‘compassionate treatment’ and a decrease in IVC 
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regurgitation and symptoms pertaining to IVC congestion were observed, further bolstering the 
feasibility of this CAVI.
[48]
     
 
Figure 2-13: CAVI; Heterotopic valve implantation at the SVC and IVC. Image from [78] 
Table 2-2: Hemodynamic parameters during implantation and follow up in chronic group as retrieved from [49] 
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However, Lauten et al. 
[49]
 addresses some limitations within the animal study, stating that in 
human patients, TR is usually observed secondary to annular dilation. Therefore, substantially 
higher venous pressures are expected, compared to those reported in the animal study. 
Furthermore, the echocardiographic parameters were not reported and the alleviation of TR was 
based solely on the reduction of the central venous pressure and the increment of the CO.
[49]
  
In order to address these limitations and expand on this work, a novel flow system utilizing an 
explanted porcine heart was established in this study; in an attempt to determine the efficacy of 
CAVI through more quantitative means.  
Additionally, in the study that involved the ‘compassionate treatment’ of TR in a patient through 
CAVI, only one valve was implanted in the IVC due to several technical complications.
[48]
 
However, there are no data available as to whether a single valve approach or a dual valve 
approach would be more ideal.
[46, 47]
 Similarly, there are also no data available on the ideal CAVI 
prosthesis.
[45, 47]
 Here, ‘ideal’ refers to both the design of the prosthesis as well as the location of 
the heterotopic implantation (IVC, SVC or both) to optimize the alleviation of the detrimental 
effects of TR; in regards to CO, JVP waveform and EROA. 
 The primary aim of this study is to establish a physiologically representative in-vitro flow 
system capable of reproducing the results from previous studies involving CAVI; through 
quantitative flow, pressure and echocardiographic assessments. However, in doing so this 
experimental set-up could then be used to determine the ideal treatment (single vs dual valve) as 
well as an optimal CAVI prosthesis. Although this is not to be done in this preliminary study, it 
aids in reflecting the potential value of this study. 
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2.6 Imaging and Flow Systems 
Cardiac Catheterization 
In the past, the presence and severity of TR was confirmed through cardiac catheterization. The 
diagnosis of TR proved to be very challenging since selective angiography into the RV would 
often distort the TV and the position of the catheter was difficult to maintain within the RV. 
However, with the introduction of 2D echocardiography and Doppler echocardiography, cardiac 




Chest radiograph is limited in its usefulness. While it may be able to distinguish prominent right 




Cardiac Magnetic Resonance 
Cardiac Magnetic Resonance (CMR) is used when the echocardiographic investigations are 
limited due to suboptimal acoustic window, the findings are equivocal or if 3-dimensional 
echocardiography is unavailable. Unlike echocardiography, CMR is not restricted by acoustic 
windows and is able to image the entire heart in any plane to provide accurate myocardial 
definition.
[4]
 CMR is currently, the best imaging modality to study RV morphology and function, 




2D echocardiography together with spectral and color flow Doppler is currently the most 
commonly used means of detecting and quantifying TR.
[44]
 TR is often identified through 
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echocardiography by TA dilation ( > 40mm) and tethering of leaflets (tenting distance >8mm).
[4]
 
Color flow Doppler is very responsive to regurgitation and therefore provides reliable semi-
quantitative assessment of its severity.
[44]
 Parasternal, apical or subcostal acoustic windows, as 
shown in figure 2-14, are often the primary planes through which TR is studied. 
 
Figure 2-14: Schematic representation of several planes of imaging commonly used in echocardiography stud ies. 
(A) 4-chamber parasternal view (B) 4-chamber apical view (C) 4-chamber subcostal view and (D) suprasternal 
view. Image from http://clinicalgate.com/echocardiography-5 
A more quantitative measurement of TR severity is provided by the vena contracta and the 
proximal isovelocity surface area (PISA).  The vena contracta reflects the cross-sectional area of 
the narrowest point in a stream (regurgitant orifice) where the maximum flow velocity is 
observed.
[4]
 An inherent limitation of measuring the vena contracta is that the regurgitant orifice 
has a complex geometry and not an idealized ‘pinhole’. Despite this, the vena contracta is used to 
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determine the regurgitant orifice area and the PISA radius which is widely accepted as a good 
quantitative indicator of the severity of regurgitation.
[4, 82]
 
In-vitro flow systems 
In-vitro flow systems are a cheaper alternative to animal models and are able to produce reliable 
data for a wide range of studies. To this end in-vitro flow systems have been used to study 
chemical mechanisms, micro-fluidic flow patterns, versatility of imaging systems and even the 
effectiveness and feasibility of medical devices.  
In a study by Jesty et al.
[38]
, platelet activation was explored through circulatory experiments that 
were performed in a flow loop. In another study, the utility of quantitative 3D-power Doppler 
angiography was analyzed using an in-vitro flow system.
[65]
 These studies help to illustrate the 
convenience afforded by flow systems, which can potentially be used as a platform for analysis. 
Moreover, Tan et al.
[76]
 further demonstrated the utility of flow systems by analyzing the left 
ventricular flow patterns, within such a system, to determine the efficacy of a bioprosthesis. 
Therefore, in-vitro experimental flow set-ups are an efficient means to streamline design and 
optimize flow studies.  
Similarly, in this study, an in-vitro flow system, utilizing an explanted porcine heart is 
established to determine the efficacy of a potential therapeutic transcather technique; CAVI. 
 
 




3.1 In-Vitro Flow Loop Set-Up 
A flow system, utilizing an explanted porcine heart, was established to emulate the venous flow 
within the right side of the heart. Physiologically, after distributing oxygen, blood is collected as 
deoxygenated blood into the SVC and IVC and directed into the right atrium of the heart. The 
blood is then pumped into the right ventricle, through the tricuspid valve, during atrial systole. 
Following which, the blood is pumped, during ventricular systole, through the pulmonary valve, 
to the pulmonary artery which carries the deoxygenated blood to the pulmonary vasculature 
(lungs) to be oxygenated. The newly oxygenated blood is then collected through the pulmonary 
vein and directed into the left atrium. During atrial systole, the oxygenated blood is pumped into 
the left ventricle through the mitral valve. The blood is then pumped through aortic valve into the 
aorta and to the rest of the body during ventricular systole. The flow system was designed to 
mimic this flow, however choosing to focus only on the right side of the heart in an effort to 
simplify the set up. 
A reservoir was used to direct the flow of the working solution (meant to represent deoxygenated 
blood) into the vena cava and ultimately into the right atrium of the explanted porcine heart. The 
hydrostatic pressure within the reservoir, due to the elevation of the working solution, ensured its 
continuous flow into the explanted heart. A pulsatile pump (SuperPump AR series, ViVitro Labs 
Inc., Victoria, BC, Canada) was used to generate the ventricular pressure to simulate ventricular 
systole of the cardiac cycle. The pump was attached to the ventricle of the explanted heart 
through a silicone tube. A schematic representation of the flow system is shown in figure 3-1A. 




Figure 3-1: In-Vitro Flow system. (A) Schematic representation of the flow system. (B) Lateral view of the flow 
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A pressure catheter system (Mikro-Tip SPR-340S, Millar Instruments Inc., Houston, TX, USA) 
was used to capture the pressure within the vena cava by inserting the catheter through the 
silicone tubes; which were meant to represent the SVC and IVC. The cardiac output was 
measured in the silicone tube representing the pulmonary artery of the explanted porcine heart 
using a flowmeter (ME16PXL, Transonic Systems Inc., Ithaca, NY, USA). The pulmonary artery 
(silicone tube) emptied out into the reservoir during the simulated cardiac cycle, thereby forming 
a closed flow circuit. The length of the tubes and height of the reservoir were optimized to 
produce pressures within the desired range. Figure 3-1B shows the lateral view of the entire flow 
system with the explanted porcine heart. 
3.2 Explanted Porcine Heart  
The explanted porcine heart was sourced from a local abattoir (Primary Industries Pte Ltd, 
Singapore) and had to be processed before being used as part of the flow system. The excess fat 
and tissue were removed carefully and the heart was subsequently flushed with water to remove 
any blood clots that might obstruct the flow and impede valve functionality. The SVC and IVC 
were subsequently cut, making sure to leave sufficient tissue for the placement of the caval 
valves, for CAVI. In order to incorporate the explanted heart into the flow system 4 silicone 
tubes had to be ‘fixed’ to the heart at the SVC, IVC, pulmonary artery and right ventricle. To 
accomplish this, 4 silicone rings were made using a 2 part silicone mix (EasyMold Silicone 
Rubber). The silicone rubber was added to a complementary cavity to be molded into the desired 
shape and thickness, as seen in figure 3-2. The silicone rings were then adhered to the silicone 
tubes using a neutral silicon sealant.  




Figure 3-2: (A) Complementary cavity used to create the (B) silicone rings which are adhered to silicone tubing 
through silicone sealant as shown in (C) and (D)  
 
A scalpel was then used to make a small insertion into the right ventricle. This was done as close 
to the apex as possible so as to not damage the tricuspid valve, chordae tendineae or the papillary 
muscles. The silicone tubes with the rings were then attached to the heart at the SVC, IVC, 
pulmonary artery and the ventricle by placing several interrupted sutures between the rings and 












Figure 3-3: (A) The interrupted sutures used to attach the silicone tubes to the heart. (B) All four tubes are 
attached to the heart 
 
Pericardium was then glued over the silicone ring and attached to the tissue to provide an 
additional seal for the tubing. This pericardial seal was done to ensure that no leaks would occur 
at the attachments to the heart. Subsequently, the heart was incorporated into the flow system 
and the data for the regurgitant model were extracted accordingly.  
After CAVI, where the caval valves were incorporated into SVC and IVC of the explanted heart, 
the data for the ventricularized state (referring to post CAVI) was extracted. Figure 3-4 shows 
the ventricularized model incorporated within the flow system. Echocardiography was used to 
ensure the heterotopic implantation of the valves were performed at the right location and 
deployed successfully, as seen in figure 3-5. 
 
A B 




Figure 3-4: The incorporation of the processed porcine heart into flow system  
 




Pulmonary Artery IVC 
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3.3 Caval Valves  
The stented valves used in this study comprised of two balloon-expandable, tubular, stainless 
steel (304 stainless steel), and bare stents with diamond-shaped cells. The diamond closed-cell 
configuration ensured the crimpability of the stent.  The stents were designed and fabricated 
(diameter 25mm, length 20mm, Meko, Hannover, Germany) (see figure 3-6) with nine crowns to 
accommodate a tri-leaflet valve. The strut was made to be 0.4mm thick to allow for the valves to 
be crimped to a smaller diameter and therefore a smaller catheter size for the deployment of the 
stented valves. Because the cyclic mechanical stresses acting on the valves in the Vena Cava are 
significantly smaller than those in the left side of the heart, the strut diameter can be reduced 
without compromising on the structural integrity.   
The bare metal stent was dip-coated with five coating layers of polyurethane (ChronoFlex AR, 
AdvanSource Biomaterials Corporation, Wilmington, MA, USA). This was done to minimize the 
paravalvular leakage of the transcatheter valve.  The porcine pericardium was harvested from a 
local abattoir (Primary Industries Pte Ltd, Singapore) and placed between two leaflet molds: of a 
tri-leaflet configuration of the human aortic leaflets. The pericardium was then treated for 20 
minutes in buffered glutaraldehyde (0.5%) at room temperature and pressure. The porcine 
pericardial leaflets were sutured onto the coated stent using 5-0 Mersilk sutures (Ethicon Endo-
Surgery, San Francisco, CA, USA). Single point attached commissure method was used to create 
the transcatheter valve.  
The optimization of the caval valve design was based on the study done by Ismail et al.
[37]
 




Figure 3-6: The transcatheter caval valves for the heterotopic implantation into the SVC and IVC. Image from[37] 
3.4 Echocardiographic Investigation 
The echocardiographic investigations were done using an ultrasonic transducer (SonixTablet, BK 
Ultrasound Inc., Peabody, Massachusetts, USA) capable of pulse-wave color Doppler 
echocardiography. Since the explanted porcine heart was submerged in water no coupling 
medium had to be used. Echocardiography was used to view the malcoaption of the tricuspid 
valve leaflets, which was a result of the dilated annulus of the regurgitant heart model. The 
regurgitant model was established by subjecting the heart to elevated pulmonary pressures, with 
the reservoir, within the flow system. Echocardiographic imaging was also used to ensure the 
proper implantation of the caval valves in the SVC and IVC for the Ventricularized heart model, 
as shown in figure 3-5.  
Stainless Steel (diamond 
shaped cells) 
Porcine Pericardium 
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Corn starch was used as the seeding particles for echocardiographic analysis, to determine the 
PISAr and for Doppler investigations. This was done for both the regurgitant and ventricularized 
heart models.  
3.4.1 Posterior 2-Chamber Long Axis Apical View 
Generally, TR is observed and quantified through either a 4 chamber apical view or a parasternal 
long axis right chamber view.
[4, 20]
 However, in this in-vitro experimental flow system only the 
right side of the heart is connected to a closed flow circuit. Therefore, to optimize the 
echocardiographic imaging window the posterior section of the heart was exposed while the 
anterior section was hidden, as seen in figure 3-4. The echocardiographic investigation is based 
on the Doppler equation: 
   
      
 
 
Where   is the frequency-shift;   is the source frequency, c is speed of ultrasound in the medium 
(soft tissue) and   represents the angle between the ultrasound scan line and the flow of the 
seeding particles (working solution). Ideally the scan lines should be parallel to the flow of the 
solution; however this is not possible in both the clinical and this experimental setting due to the 
technical limitations since the transducer cannot be placed perfectly parallel to the flow profile 
through the TV such that    . Nevertheless, the generally accepted range of less than 60 
degrees was adhered to in this experiment. In addition, this experiment involves the comparative 
analysis between the regurgitant state and the ventricularized state, thus any errors associated to 
the angle, while still within the accepted accuracy range, can be negated.  
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To achieve the optimal acoustic window, and the smallest angle between the scan lines and flow, 
a posterior 2 chamber long axis apical view was adopted, as shown in figure 3-7.  
 
Figure 3-7: Posterior 2 chamber long axis apical view. (A) Lateral view of the scan lines (B) Superior view of the 
posterior section of the heart  
3.4.1 Quantification 
In this study the level of regurgitation was determined both qualitatively, through pressure and 
flow waveforms with echocardiographic images of the malcoaption of the leaflets, and 
quantitatively, through echocardiographic investigations to determine the PISAr and effective 
regurgitant orifice area (EROA).  
Tricuspid regurgitation was quantified via 2D colour Doppler Proximal Isovelocity Surface Area 
(PISA) measurements as is the clinical standard, through non-invasive imaging. This method is 
based on the principal of conservation of mass: as blood approaches the regurgitant orifice, 
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From the conservation theory, it follows that the volumetric flow rates on either side of the 
tricuspid valve must be equal. This is represented by:  
      
Where Q represents the volumetric flow rate which is defined as: 
                
From this it follows that: 
                                 
The area proximal to the regurgitant orifice area, at the right ventricle, can be estimated through 
2D color Doppler echocardiography to be a hemispherical distribution of velocity vectors. It can 
therefore be represented by: 
         
  
The radius can be determined through the 2D color echocardiographic investigations as the radial 
distance from the regurgitant orifice area to the isovelocity surface area. This surface area is 
dependent upon the aliasing velocity that has been defined. This would then imply: 
                            
The area of the flow on the other side, in the right atrium, is referred to as the Effective 
Regurgitant Orifice Area (EROA) and it is one of the key determinants of the severity of the TR. 
The EROA is the cross sectional area of the vena contracta and therefore is also the point of the 
maximum velocity. From this, it follows: 
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Hence, 
     
                      
                
 
The maximum velocity can be determined through continuous wave color Doppler or pulse wave 
Doppler, measured at the central axis of the regurgitant jet. Figure 3-8 illustrates the 2D color 
Doppler echocardiographic method described.  
 
Figure 3-8: 2D color Doppler echocardiography method used to determine the effective regurgitant orifice area  
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While this method is the clinical standard it is not without its assumptions and limitations. The 
hemispherical flow convergence is based on the assumption that the regurgitant area is small and 
a perfectly round orifice. This is one of the limiting factors since the regurgitant area often has a 
complex shape and is dependent upon causality of TR such as annular dilation, leaflet 
calcification and RV enlargement.  
Another limitation is the Doppler ultrasound’s ability to only detect velocity components aligned 
with the direction of the ultrasound beam. Inability of the ultrasound to detect the velocity 
perpendicular to the scan lines means the velocities observed are a projection of the actual 
velocity. However, the true value can be modulated with the cosine of the angle between 














4.1 Preliminary Echocardiographic Imaging 
After the regurgitant model was established, the annular dilation was observed through 
echocardiographic investigations. This was done to ensure that the regurgitation was due to 
annular dilation, right ventricular dilation and papillary muscle displacement rather than a leak 
within the flow system. Figure 4-1 shows the coaption of the Tricuspid valve over a single 
cardiac cycle at various points in time. As seen in the images, the leaflets fail to coapt due to the 
tethering of the leaflets which are a result of the papillary muscles displacement brought about 
by the annular and ventricular dilation. While the regurgitant orifice area is observable, more 
quantitative measures are required to demonstrate the efficacy of CAVI. 
Therefore, the relevant data for the flow, pressure and echocardiographic parameters (PISAr and 
EROA) were extracted. The successful deployment of the caval valves into the SVC and IVC 
established the ventricularized model. This was confirmed through echocardiography as well, as 
seen in figure 3-5. After CAVI, the native leaflets were observed for any notable changes over a 
single cardiac cycle, as shown in figure 4-2. The leaflets demonstrated better coaption; and a 
smaller regurgitant orifice area was observed. However, while this qualitative means of 
measurement is useful in reflecting the utility of the flow system, more quantitative measures 
were required to determine the efficacy of the therapeutic procedure. 
The images show in figures 4-1 and 4-2 were extracted using Matlab 2013b. 




Figure 4-1: Regurgitant Tricuspid Valve Mechanics (A) The opening of the tricuspid valve in the regurgitant 
model. (F) The malcoaption of the tricuspid valve during systole due to papillary muscle displacement  
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Figure 14-2: Ventricularized Tricuspid Valve Mechanics (A) Opening of the tricuspid valve in the Ventricularized 
model. (F) Improved coaption of the tricuspid valve during systole after CAVI 
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The pressure profiles of the regurgitant and post-CAVI (ventricularized) state were plotted 
parallel to the time stamps of the echocardiographic images, as shown in figure 4-3. 
 
Figure 4-3: Pressure Profiles of (A) Regurgitant state and (B) Ventricularized state and the corresponding time 
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4.2 Cardiac Output 
The cardiac output in the pulmonary artery was recorded in both the regurgitant model and the 
Ventricularized model. Pulsatile flow was observed in both models since a pulsatile pump 
(attached to the right ventricle) was programmed to mimic the ventricular systole of the cardiac 
cycle. The sinusoidal flow waveform, shown in figure 4-4A, corresponds to the CO over 4 
seconds. There is a notable difference in the CO between the regurgitant model and the 
Ventricularized model, with the latter being greater than the former.  
The integral of the CO was taken over one minute, as reflected in figure 4-4B, the CO for the 
regurgitant model was determined to be 0.87206 liters per minute while the CO for the 
ventricularized model was found to be 1.9373 liters per minute. Therefore the CO increased by a 
factor of 2.22 after CAVI. This is similar to the findings reported by Lauten et al. 
[49]
 in their 
animal study; where the regurgitant CO decreased by a factor of 1.78. While this result is 
consistent with the expected trend (CAVI improves CO) the difference in magnitude can be 
attributed to a number of reasons such as the size of heart, difference in artificial introduction of 
regurgitation and the state of the soft tissue. Note: Matlab 2013b was used to determine the 
integral of the flow data. 
Negative flow was also observed within the pulmonary artery, as seen in figure 4-4A, in both the 
regurgitant and the ventricularized model.  
Ultimately, these observations allude to the efficacy of CAVI and further bolster the preliminary 
echocardiographic findings. Still, the pressure profiles of the JVP, PISAr and the EROA were 
required to establish a more quantitative means of analysis.  




Figure 4-4: (A) The pulsatile cardiac output flow waveform over 4 seconds. (B) The integral of the flow 
waveform illustrating the volumetric flow 
4.3 Jugular Venous Pressure Profiles 
Under physiological conditions the Jugular Venous Pressure (JVP) waveform is characterized by 
the ‘a’, ‘c’ and ‘v’ wave and the ‘x’ and ‘y’ decent, as illustrated in the figure 4-5. The shape of 
the JVP coincides with the activity of the heart during the cardiac cycle. The ‘a’ wave 
corresponds to the atrial contraction which causes the pressure to increase and subsequently fall 
as the contraction slows. When the tricuspid valve closes there is a small increase in the pressure 
which is representative of the ‘c’ wave. The ‘x’ decent occurs during ventricular systole, where 
the atrium expands and relaxes. The rising ‘v’ wave follows the ‘x’ decent and occurs during 
systole due to the rapid filling of the atrium. As the pressure in the atrium becomes greater than 
A 
B 
E ~ ± 0.5%  
E ~ ± 0.5% 
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the ventricle, the tricuspid valve opens, and the passive filling of the ventricle occurs resulting in 
the ‘y’ decent.  
With tricuspid regurgitation, an abnormal JVP with an absent ‘x’ decent and a dominant ‘v’ 
wave would be observed. This is due to the malcoaption of the tricuspid valve leaflets causing 
the rising pressure in the right ventricle, during systole, to be distributed in the atrium as well.  
  
Figure 4-5: Illustration of the JVP. Image from [42] 
 
The pressure profiles for both the regurgitant and ventricularized model were captured using the 
pressure catheter placed in the SVC and IVC. The pressure waveform recorded for the 
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regurgitant model had a dominant ‘v’ wave and an absent ‘x’ descend – features representative 
of tricuspid regurgitation in the JVP. The peak pressure for the regurgitant pressure profile is 
47.52mmHg and 42.26mmHg for the IVC and SVC, respectively.  
In the ventricularized heart model, the pressure profile had a restored ‘x’ descend and the ‘v’ 
wave was no longer dominant. The maximum pressure observed was that of the ‘a’ wave and 
was recorded as 36.29mmHg and 39.12mmHg for the IVC and the SVC respectively.  
The pressure profiles for both heart models are represented in figure 4-6. The central venous 





Figure 4-6: The pressure profile observed in the SVC and IVC for both the regurgitant (red) and Ventricularized 
(blue) heart model.  
E = ± 1.5mmHg 
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4.4 Echocardiographic Investigation 
The echocardiographic parameters were important in quantifying regurgitation for both the 
regurgitant and the ventricularized model, in order to determine the efficacy of the treatment 
method. The PISAr, the radial distance from the regurgitant orifice area to the isovelocity surface 
area, was measured using 2D color Doppler echocardiography. 
The isovelocity surface area was calculated by taking the radial distance parallel to the beam 
formation, as seen in figure 4-7. The parallel radial distance was used as the PISAr 
measurements, to prevent errors associated to angular adjustments, in determining the EROA; 
which was measured to be 6.73mm and 4.81mm for the regurgitant state and the ventricularized 
state, respectively. The aliasing velocity for the regurgitant state was found to be 52cm/s, and 
51cm/s for the Ventricularized state.  
The maximum velocity was determined using a pulse wave Doppler echocardiography along 
several points on the central axis of the regurgitant jet. The maximum velocity for the regurgitant 
model was 68.0cm/s while the maximum velocity for the ventricularized model was 82.2cm/s. 
The Doppler echocardiography for both the regurgitant and ventricularized model can be seen in 
figure 4-8.  
Pulse wave systems have an intrinsic limitation; that at a given sampling frequency, pulse 
repetition frequency (PRF), the maximum Doppler frequency that can be measured without 
aliasing is half that of the PRF. Low velocities are examined using low PRF since a longer 
interval between pulses allows the scanner to better identify slow flow. Conversely, high pulse 
frequencies are used to determine high velocities. Therefore, to determine the maximum velocity 
in both the regurgitant and ventricularized model a PRF of 12.5 kHz (maximum) was used.  




Figure 4-7: The echocardiographic study to determine the PISAr for (A) Regurgitant model and (B) 
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However, using a high PRF might result in lower velocities going undetected. For this reason the 
PRF used in the color Doppler, to determine the PISAr, was 6.7 kHz. 
Similarly, other factors like the depth, gain and baseline were optimized to best extract the 
relevant data.  
EROA was determined as:  
 
     
                      
                
 
EROA is based on the principal of conservation of mass. The results of the echocardiographic 
study, summarized in table 3, demonstrate that CAVI had successfully reduced the EROA by a 
factor of 2.42.  
Table 4-1: Summary of the echocardiographic results  



































































In this study the efficacy of CAVI – the percutaneous heterotopic implantation of caval valves in 
the vena cava– is analyzed as a potential therapeutic treatment for tricuspid regurgitation. To do 
this, a novel flow system with an explanted porcine heart was designed to capture the 
pathophysiological representation of TR. The explanted heart was processed and made into a 
regurgitant model by inducing annular and ventricular dilation through hydrostatic pressure. The 
cardiac output, central venous pressure and the relevant echocardiographic parameters to 
quantify regurgitation were extracted. 2 caval valves were then placed into the vena cava to 
create the ventricularized model and the quantitative parameters were again extracted, and 
studied against that of the regurgitant model.  
The annular dilation and tethering of the leaflets were observed in the regurgitant model through 
echocardiography, as seen in figure 4-1. The opening and closing of the leaflets, in the 
ventricularized model, were also observed, as seen in figure 4-2, to qualitatively visualize the 
improvement in the coaption of the leaflet. This demonstrates that the increase in atrial pressure 
due to CAVI is able to suppress the regurgitation during systole, as a smaller regurgitant area is 
observed. However, this would only be a qualitative assertion and not a quantitative one. 
Moreover, some extent of acoustic shadowing is observed which urges the need for a more 
quantitative determination of the efficacy of the procedure.  
Dr Lauten et al.
[49]
 reported, in his animal study, an increase in cardiac output with CAVI and 
concluded that the procedure alleviated the detrimental effects of STR by doing so. With 
tricuspid regurgitation, a reduction of the cardiac output is expected due to the retrograde flow of 
blood into the atrium instead of the ventricular outflow tract. Similar to Dr Lauten’s findings, 
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this study reports a significant improvement of the CO in the ventricularized model when 
compared with the CO of the regurgitant model, as seen in figure 4-4.  
Furthermore, from the figure 4-4A, the pulsatile nature of the flow is appropriately captured 
which lends credibility to the flow system being physiologically representative. Figure 4-4B, 
reflects the integration of the outflow over one minute, indicating the significant improvement in 
the volumetric flow through the pulmonary artery in the ventricularized model as opposed to the 
regurgitant model. While this demonstrates the efficacy of the procedure there are certain 
limitations of the flow system that must be addressed.  
One of the limitations is magnitude of the volumetric flow in both diseased and treated model. 
Physiologically, the CO in a healthy individual is about 4.5 liters per minute and less in patients 
with TR – depending on severity. However, in this study the CO reported for the regurgitant 
model is 0.87206 l/min and 1.9373 l/min for the treated (ventricularized) model. This is due to 
the loss of the muscular recoil of the porcine heart and the manner in which ventricular systole is 
mimicked – pulsatile pump connected to the ventricle. Due to this, the stroke volume is not 
increased to the physiological range to prevent the pump from creating a strong jet within the 
ventricle during systole. This jet could potentially impede the natural functionality of the 
tricuspid leaflets and affect their coaption, which would compromise the results. Therefore, the 
stroke rate was optimized such that CAVI showed a marked improvement in the CO without 
affecting the functionality of the leaflets; which was confirmed through echocardiography.  
Another drawback is the negative flow observed in the pulmonary artery. This can be attributed 
to the piston pump used to simulate the ventricular systole. When the piston draws back it creates 
a negative pressure (vacuum) that results in recirculation and backflow. Despite this limitation, 
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the flow is largely positive and pulsatile, and the CO has been shown to improve significantly 
with CAVI which supports its validity as a therapeutic solution to TR. This negative flow could 
have been mitigated further by adding an additional dampening component directly after the 
pump and before connecting to the heart. The reason why this was not implemented in the final 
set-up was due to the trade-off between mitigating the negative flow and maintaining the 
physiological pressure profiles; the latter being more pertinent to the overall analysis. 
With TR the central venous pressure is heightened which in turn results in several comorbidities 
such as hepatosplenomegaly, peripheral edema and ascites. This was also reported in the animal 
study done by Dr Lauten et al.
[49]
 In a healthy heart, the jugular venous pressure waveform – 
represents the pressure in the right atrium and vena cava – is characterized by the ‘a’ wave, ‘x’ 
descend, ‘v’ wave and the ‘y’ descend, as seen in figure 4-5. Each of these features 
corresponding to a part of the cardiac cycle; ‘a’ wave the atrial contraction, ‘x’ descend the 
ventricular systole, ‘v’ wave the rapid passive filling of the atrium and the ‘y’ descend the 
opening of the tricuspid valve.   
However, with TR the JVP is modified and a single large peak is formed, as seen in figure 4-6. 
This is because the ‘x’ descend which used to indicate a drop in pressure, during ventricular 
systole, as the atrium relaxed and expands, is absent. The absence is a result of the regurgitant jet 
in the right atrium which instead increases the pressure within the atrium. This is further 
exacerbated by the rapid passive filling of the atrium which results in a single dominant ‘v’ 
wave, having merged with the ‘a’ wave. This was observed in the pressure profiles extracted 
from both the SVC and IVC in the regurgitant model of the flow system.  
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Moreover, with the ventricularized model the JVP was returned to the physiological state in both 
the SVC and IVC, as seen in figure 4-6. The ‘x’ descend was restored and the ‘v’ wave was no 
longer dominant with the peak pressures reported from the ‘a’ wave. The central venous pressure 
was also significantly lower. These results support the observations of Dr Lauten’s animal study 
and the effectiveness of CAVI as a therapeutic procedure.  
Furthermore, in the animal study the peak pressures were reported without the JVP waveforms 
and STR was introduced via deliberate damage to the leaflet using a 0.07 inch wire blade. 
Therefore, the regurgitation reported occurred without annular dilation and was significantly 
lower than the physiological pressures expected. These limitations, highlighted by Lauten et al. 
[48]
, were addressed in this novel flow system using an explanted porcine heart. Therefore, adding 
credibility to the flow system in highlighting the efficacy of CAVI as a potential new therapeutic 
method.  
The echocardiographic parameters extracted from this study also support the efficacy of CAVI. 
The proximal isovelocity surface area radius was found to be significantly smaller in the treated 
(ventricularized) model than in the regurgitant model; 4.81mm in treated and 6.73mm in the 
regurgitant. CAVI contains the elevated pressure within the right atrium; which reduces the 
amount of regurgitation, since the heightened pressure would ‘flatten’ the pressure gradient from 
the ventricle to the atrium, during systole.   
After the aliasing velocities for each of the models were determined, the maximum velocity of 
the regurgitant jet was analyzed using pulse wave Doppler color echocardiography. The 
maximum velocity for the treated model, 82.2 cm/s, was much higher than the regurgitant model, 
68.0cm/s. This was as expected since the echocardiographic method, for quantification, is based 
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on the principal of conservation of volumetric flow. Hence, the maximum velocity was observed 
for the ventricularized model which has the smaller PISAr.  
With the PISAr, aliasing velocities, and the maximum velocities the effective regurgitant orifice 
area was determined, for both the treated and diseased model. The results demonstrate that CAVI 
could potentially be an effective transcatheter therapeutic technique to treat STR; since the 
EROA for the treated model was 2.42 times smaller than the regurgitant model.  
However, there are some limitations that must be addressed in this study. Firstly, pulse wave 
color Doppler echocardiography was used to determine the maximum velocity. While this is 
possible, it is limited to point based analysis of the central axis of the regurgitant jet, which 
might be subjected to human error. Ideally the maximum velocity is determined using continuous 
wave Doppler color echocardiography which mitigates the possibility of human error.  
Secondly, despite the encouraging flow, pressure and echocardiographic results, the EROA for 
the treated model is 0.50   . While this is 2.42 times smaller than the EROA in the regurgitant 
model it is still considered severe. TR is considered to be severe when the EROA is greater than 
0.4   . However, this is explained by the inherent limitations in this study. 
Finally, it is important to note that this study was done with an explanted porcine heart and 
therefore there are certain intrinsic limitations. The heart model, while processed to be 
complementary to the flow system, is still unable to produce any muscular recoil or recovery. 
Still, using an explanted porcine heart provided an extremely physiologically, and 
pathophysiologically, representative model. STR was introduced through deliberate accentuated 
hydrostatic pressure which resulted in annular dilation. While the model was able to demonstrate 
how CAVI would be able to reduce the EROA – by containing the elevated pressure within the 
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right atrium – it is unable to emulate the muscular activity and recoil. This is reflected by the still 
severe EROA in the treated model; although significantly improved.  
 Aside from the limitations of the flow system, the potential drawbacks of the technique must 
also be discussed. CAVI, being a heterotopic implantation, does not affect the native tricuspid 
leaflets and ‘contains’ the elevated pressures within the atrium. While this reduces the central 
venous pressure and improves the cardiac output it may pose long term detrimental effects on the 
right atrium. The right atrium being subjected to persistent elevated pressures might undergo 
remodeling and potentially develop atrial fibrillation. More studies have to be done to determine 
the likelihood as well as the possible predictors (parameters) that might lend insight into this 
investigation.  
Ultimately, having acknowledged the potential limitations of the both the flow system and the 
technique, CAVI has proven to be a very promising transcatheter therapeutic procedure that 
could potentially expand the available techniques to treat tricuspid regurgitation. The flow 
system developed in this study was able to demonstrate the benefits of techniques that were 
highlighted by Lauten et al. 
[48]
 and additionally provided quantitative assessment on the 






6.1 Future Works 
The flow system was optimized after several iterations, through the use of several hearts, to 
ensure that the results obtained were not compromised due to random error. Having incorporated 
an explanted porcine heart, the complex morphology of the tricuspid valve, annulus and sub 
apparatus like the papillary muscles and chordae tendineae were ‘captured’ in the flow system. 
This further bolsters the novelty as well as the physiological representation of both the diseased 
and treated state. However, with further iteration an even greater degree of complexity could 
potentially be introduced to achieve an even more representative model.  
One possible complexity would be the introduction of a pericardial membrane around the heart 
designed to prevent its excessive excursion during the simulated cardiac cycle. This would be 
useful in circumventing the lack of muscular recoil which tends to dilate the heart progressively 
throughout the study. This pericardial fold however, should not impede the ability to carry out 
echocardiographic assessments on the explanted heart. Therefore it could be a potential 
development in making the flow system even more representative.  
Moreover, the flow system with the explanted heart could be used to study the effectiveness of 
various medical procedures and devices. It could also likely be used to expedite research by 
serving as an initial test for the relevant procedures and devices before animal study; potentially 
increasing the success rates.  
Devices with unique means of anchorage and fixation could be studied in the flow system, by 
leveraging on the complexity of the explanted heart, without having to conduct animal studies
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initially; which are often time consuming and expensive. It could also be used to demonstrate the 
feasibility of a procedure and predict the likelihood of success.    
In addition, the flow system could be used in research where cardiology is concerned. A 
phantom silicone model could be established in conjunction with the explanted heart model and 
particle image velocimetery could be used to ascertain the flow profile within the heart. A 
simulatory study could also be established to reflect the data extracted from the flow system and 
could potentially be used as a predictive template for various devices and procedures. These 
methods could help to provide a more holistic interpretation of a medical device or procedure.  
Langendoff Preparation 
The mammalian heart perfusion method conceptualized by Oscar Langendoff in 1985 might lead 
to some very interesting and potentially significant developments. The Langendoff preparation of 
a heart model has been used to study basic heart physiology, myocardial function and various 
human diseased states such as hypertension, ischemia and reperfusion injury.
[6]
 In this study, the 
efficacy of heterotopic implantation of caval valves in the vena cava was investigated as a 
potential solution to TR and therefore the Langendoff method is not  entirely applicable. This is 
because the Langendoff heart model is perfused in a retrograde fashion through the aorta which 
forces the aortic valve to close; forcing the solution into the coronary vessels which normally 
supply the heart tissue with blood. This method keeps the heart beating for several hours where 
crucial data is extracted. Figure 5-1 illustrates a working model of the Langendoff heart 
established in a study done by R.M. Bell et al.
[6]
  




Figure 6-1: Schematic representation of a working Langendoff heart model done by R.M. Bell et al. [6] 
Despite not being directly applicable, some aspects of the Langendoff model could increase the 
physiological representation of our explanted heart flow system. For example, the Krebs 
Henseleit Buffer could be used as the perfusing solution instead of a starch solution. However, 
the feasibility of echocardiographic analysis must not be compromised and therefore further 
investigations would be required. On the other hand, whole blood perfusion could be considered 




There have also been studies that have attempted to use electrical stimulation together with 
image analysis to study other comorbidities such as ventricular fibrillation with some success.
[59]
 
While this would be an interesting and useful idea to incorporate into our own model, it would 
not be feasible at this stage. One of the primary reasons is the need to immobilize the tissue using 
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uncoupling drugs which have significant effect on the cell electrophysiology.
[59]
 Moreover, the 
cardiac movement incited by electrical stimulation has to be coordinated very precisely to 
emulate a successful cardiac cycle. The time limitation should also be taken into consideration 
since electrical simulation would only be effective for a small window post explantation. 
Furthermore, the induced cardiac cycle has to be strong enough to create the physiological 
pressure waveforms; which based on current studies are not sufficient. 
Therefore, while the current flow system does produce favorable results and is sufficiently 
representative of the physiological state, there are still several methods to be studied that could 
potentially advance the complexity of this novel flow system even further. 
Ultimately in this study, the effectiveness of CAVI, as a percutaneous transcatheter treatment for 
tricuspid regurgitation, was analyzed. This was done through a novel flow system that utilized an 
explanted porcine heart. Through the incorporation of the heart, the complexities associated with 
the morphology of the tricuspid valve, annulus, papillary muscle and chordae tendineae were 
introduced into the flow system, allowing a more physiological representation.  
The diseased model of the heart was made by deliberately exposing the right atrium to elevated 
hydrostatic pressure resulting in annular dilation and severe tricuspid regurgitation. The 
ventricularized model was made by heterotopic implantation of 2 caval valves into the superior 
and inferior vena cava of the diseased model.  
The corresponding results of the study were supportive of a previous animal study done on this 
procedure. There was a significant increase the cardiac output and decrease in the central venous 
pressure which was similarly reported in the previous study. However, unlike the previous study, 
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tricuspid regurgitation was introduced with annular dilation and the jugular venous waveforms 
were reported in full, addressing the limitations of the previous study.  
Moreover, echocardiographic assessments were made to quantify the levels of regurgitation in 
both the diseased and treated model. These results again were favorable, lending further viability 
to CAVI as a potential therapeutic procedure.  
While there are several intrinsic limitations of using an explanted porcine heart, it still adds to 
the complexity of the flow system and increases its physiological representation of the diseased 
model. It also provides unique insight to the potential shortcomings of CAVI which warrants 
more study. 
In conclusion, CAVI increases the cardiac output, reduces the central venous pressure and 
reduces the effective regurgitant orifice area, thereby alleviating the detrimental effects of severe 
tricuspid regurgitation. Although more research is required to comprehend the long term effects 
of the heterotopic implantation of the caval valves in the vena cava, CAVI could potentially 
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A P P E N D I X  A :  M A T L A B  C O D E  
Cardiac Output .......................................................................................................................................... 1 
Pressure Waveform ................................................................................................................................... 5 
One Cycle with Echocardiographic Time ppoints .................................................................................... 8 
function Master_Post_Processing 
% This function will plot the data extacted from the pressure catheter and 
% the flow meter. The function will plot the 4 cycles and determine the 
% maximum pressure of the average of the 4 peaks and the flow rate. 
% 
% Author: Karthic 





Regurgitation flow in the PA (IVC Run), the time step is 0.01s and the vertical axis is in litres per min 
Divide by 60 to change it to litres per second rather than per min 
% Data 
% Regurgitant 
%Cardiac_Output_IVC_run = xlsread('Regurgitant_Data.xlsx','B2:B401')/60; 
Cardiac_Output_IVC_run = xlsread('Regurgitant_Data_2.xlsx','B2:B402')/60; 
%Cardiac_Output_IVC_time = xlsread('Regurgitant_Data.xlsx','A2:A401'); 
Cardiac_Output_IVC_time = xlsread('Regurgitant_Data_2.xlsx','A2:A402'); 
 
% Ventricularized 
Cardiac_Output_V_IVC_run = xlsread('Ventricularization_1.xlsx','B2:B406')/60; 
%Cardiac_Output_V_IVC_run = xlsread('Ventricularization_2.xlsx','B2:B406')/60; 
Cardiac_Output_V_IVC_time = xlsread('Ventricularization_1.xlsx','A2:A406'); 
%Cardiac_Output_V_IVC_time = xlsread('Ventricularization_2.xlsx','A2:A406'); 
 
x_CO_IVC = length(Cardiac_Output_IVC_time); 
Cardiac_Output_IVC_time = (1:x_CO_IVC) * 0.01; 
 
x_CO_V_IVC = length(Cardiac_Output_V_IVC_time); 
Cardiac_Output_V_IVC_time = (1:x_CO_V_IVC) * 0.01; 
 
% Plot for the Regurgitation CO in IVC run 
% figure(1); 
 
[curveIVC, goodness, output] = fit(Cardiac_Output_IVC_time',... 




% title('\fontsize{16} Regurgitant Cardiac Output_1 Flow Waveform',... 
% 'fontweight','bold','fontname','Monotype Corsiva'); 
% xlabel('\fontsize{10} Seconds [s]','fontweight','bold'); 
% ylabel('\fontsize{10} Litres per second [L/s]','fontweight','bold'); 
% legend('Data points','CO','location','best'); 
 
% subplot(2,1,2) 
int_IVC_run = integrate(curveIVC,Cardiac_Output_IVC_time,0); 
CO_flowrate_IVC = int_IVC_run(end)*(60/Cardiac_Output_IVC_time(end)); 
% plot(Cardiac_Output_IVC_time,int_IVC_run); 
% title('\fontsize{16} Integral of Regurgitant Cardiac Output over 4 seconds',... 
% 'fontweight','bold','fontname','Monotype Corsiva'); 
% xlabel('\fontsize{10} Seconds [s]','fontweight','bold'); 
% ylabel('\fontsize{10} Litres per min [L/s]','fontweight','bold'); 
% text(2,0,['Cardiac Output per min = ',num2str(CO_flowrate_IVC), ' L/min']); 
 
 
% Regurgitation flow in the PA (SVC Run) , the time step is 0.01s and the vertical 
% axis is in litres per min 




%Cardiac_Output_SVC_run = xlsread('Regurgitant_Data.xlsx','H2:H408')/60; 
Cardiac_Output_SVC_run = xlsread('Regurgitant_Data_2.xlsx','H2:H405')/60; 
%Cardiac_Output_SVC_time = xlsread('Regurgitant_Data.xlsx','G2:G408'); 
Cardiac_Output_SVC_time = xlsread('Regurgitant_Data_2.xlsx','G2:G405'); 
 
% Ventriculrized 
Cardiac_Output_V_SVC_run = xlsread('Ventricularization_1.xlsx','H2:H398')/60; 
%Cardiac_Output_V_SVC_run = xlsread('Ventricularization_2.xlsx','H2:H404')/60; 
Cardiac_Output_V_SVC_time = xlsread('Ventricularization_1.xlsx','G2:G398'); 
%Cardiac_Output_V_SVC_time = xlsread('Ventricularization_2.xlsx','G2:G404'); 
 
x_CO_SVC = length(Cardiac_Output_SVC_time); 
Cardiac_Output_SVC_time = (1:x_CO_SVC) * 0.01; 
 
x_CO_V_SVC = length(Cardiac_Output_V_SVC_time); 
Cardiac_Output_V_SVC_time = (1:x_CO_V_SVC) * 0.01; 
 
% Plot for the Regurgitation CO in the SVC run 
% figure(2); 
 
[curveSVC, goodness, output] = fit(Cardiac_Output_SVC_time',... 




% title('\fontsize{16} Regurgitant Cardiac Output_2 Flow Waveform',... 
% 'fontweight','bold','fontname','Monotype Corsiva'); 
% xlabel('\fontsize{10} Seconds [s]','fontweight','bold'); 
% ylabel('\fontsize{10} Litres per second [L/s]','fontweight','bold'); 
% legend('Data points','CO','location','best'); 
 
% subplot(2,1,2) 
int_SVC_run = integrate(curveSVC,Cardiac_Output_SVC_time,0); 
CO_flowrate_SVC = int_SVC_run(end)*(60/Cardiac_Output_SVC_time(end)); 
% plot(Cardiac_Output_SVC_time, int_SVC_run); 
% title('\fontsize{16} Integral of Regurgitant Cardiac Output over ~4 seconds',... 
% 'fontweight','bold','fontname','Monotype Corsiva'); 
% xlabel('\fontsize{10} Seconds [s]','fontweight','bold'); 
% ylabel('\fontsize{10} Litres per min [L/s]','fontweight','bold'); 
% text(2,0,['Cardiac Output per min = ',num2str(CO_flowrate_SVC),' L/min']); 
 
 
% Plotting the Flow for the Reurgitation both in the IVC and SVC in both 
% cases of ventricularization and regurgitation 
 
% Ventricularization plotting details 
[curve_V_IVC, goodness, output] = fit(Cardiac_Output_V_IVC_time',... 
    Cardiac_Output_V_IVC_run,'Smoothingspline'); 
int_V_IVC_run = integrate(curve_V_IVC,Cardiac_Output_V_IVC_time,0); 
CO_flowrate_V_IVC = int_V_IVC_run(end)*(60/Cardiac_Output_V_IVC_time(end)); 
 
[curve_V_SVC, goodness, output] = fit(Cardiac_Output_V_SVC_time',... 
    Cardiac_Output_V_SVC_run,'Smoothingspline'); 
int_V_SVC_run = integrate(curve_V_SVC,Cardiac_Output_V_SVC_time,0); 
CO_flowrate_V_SVC = int_V_SVC_run(end)*(60/Cardiac_Output_V_SVC_time(end)); 
 
% Comparative analysis between Regurgitation and Ventricularization 
Average_regurgitant_flow = (CO_flowrate_IVC + CO_flowrate_SVC)/2; 
Average_ventricularization_flow = (CO_flowrate_V_SVC+CO_flowrate_V_IVC)/2; 
 
figure(1) 
% Regurgitation; red is used to represent the dieseased state 
subplot(2,1,1) 
[curveIVC, goodness, output] = fit(Cardiac_Output_IVC_time',... 




'\fontsize{16} Cardiac Flow Output Waveforms: Regurgitant Vs Ventricularized',... 
'fontname','Times New Roman'); 
hold on; 
[curveSVC, goodness, output] = fit(Cardiac_Output_SVC_time',... 
    Cardiac_Output_SVC_run,'Smoothingspline'); 
 
plot(curveSVC,'r',Cardiac_Output_SVC_time,Cardiac_Output_SVC_run,'k.'); 
% Ventricularization; blue is used to represent the corrected state 
plot(curve_V_IVC,'b',Cardiac_Output_V_IVC_time,Cardiac_Output_V_IVC_run,'k.'); 
plot(curve_V_SVC,'b',Cardiac_Output_V_SVC_time,Cardiac_Output_V_SVC_run,'k.'); 
legend('Data points for Regurgitant State',... 
    'CO for 1st Regurgitant State','Data points for Regurgitant State',... 
'CO for 2nd Regurgitant State','Data points for Ventricularized State',... 
'CO for 1st Ventricularised State','Date points for Ventricularized State',... 
'CO for 2nd Ventricularized State','location','northeast'); 
xlabel('\fontsize{14} Seconds [s]','fontname','Times New Roman'); 







'\fontsize{16} Integral of Cardiac Flow Output: Regurgitant vs Ventricularized',... 





xlabel('\fontsize{14} Seconds [s]','fontname','Times New Roman'); 
ylabel('\fontsize{14} Litres per min [L/s]','fontname','Times New Roman'); 
text(1.65,0,['\fontsize{12} Average Cardiac Output during Regurgitation per min = ',... 
    num2str(Average_regurgitant_flow),' L/min']); 
text(2.5,0.0725,[... 
    '\fontsize{12} Average Cardiac Output after Ventricularization per min = ',... 




Pressure for the IVC 
%IVC_Pressure = xlsread('Regurgitant_Data.xlsx','E2:E406'); 
IVC_Pressure = xlsread('Regurgitant_Data_2.xlsx','E2:E404'); 
%V_IVC_Pressure = xlsread('Ventricularization_1','E2:E401'); 
V_IVC_Pressure = xlsread('Ventricularization_2','E2:E403'); 
 
xpivc = length(IVC_Pressure); 
time_ivc = (1:xpivc)*0.01; 
 
Vxpivc = length(V_IVC_Pressure); 
time_V_ivc = (1:Vxpivc)*0.01; 
 
% Plot of pressure in the IVC 
% figure(4); 
% plot(time_ivc,IVC_Pressure); 
% title('\fontsize{16} Regurgitant Pressure Profile in IVC','fontweight',... 
%     'bold','fontname','Monotype Corsiva'); 
% xlabel('\fontsize{10} Seconds [s]','fontweight','bold'); 
% ylabel('\fontsize{10} Pressure [mmHg]','fontweight','bold'); 
% 
% index_P_IVC_min = find(min(IVC_Pressure) == IVC_Pressure); 
% time_min = time_ivc(index_P_IVC_min); 
% P_IVC_min = IVC_Pressure(index_P_IVC_min); 
% 
% index_P_IVC_max = find(max(IVC_Pressure) == IVC_Pressure); 
% time_max = time_ivc(index_P_IVC_max); 
% P_IVC_max = IVC_Pressure(index_P_IVC_max); 
% 
% strminivc = ['Minimum = ',num2str(P_IVC_min)]; 
% text(time_min,P_IVC_min,strminivc,'HorizontalAlignment','left'); 
% 




% Pressure for SVC 
%SVC_Pressure = xlsread('Regurgitant_Data.xlsx','K2:K405'); 
SVC_Pressure = xlsread('Regurgitant_Data_2.xlsx','K2:K403'); 
%V_SVC_Pressure = xlsread('Ventricularization_1','K2:K401'); 
V_SVC_Pressure = xlsread('Ventricularization_2','K2:K401'); 
 
xpsvc = length(SVC_Pressure); 
time_svc = (1:xpsvc)*0.01; 
 
Vxpsvc = length(V_SVC_Pressure); 
time_V_svc = (1:Vxpsvc)*0.01; 
 
% Plot of pressure in the SVC 
% figure(5); 
% plot(time_svc,SVC_Pressure); 
% title('\fontsize{16} Regurgitant Pressure Profile in SVC','fontweight',... 
%     'bold','fontname','Monotype Corsiva'); 
% xlabel('\fontsize{10} Seconds [s]','fontweight','bold'); 
% ylabel('\fontsize{10} Pressure [mmHg]','fontweight','bold'); 
% 
% index_P_SVC_min = find(min(SVC_Pressure) == SVC_Pressure); 
% time_min = time_svc(index_P_SVC_min); 
% P_SVC_min = SVC_Pressure(index_P_SVC_min); 
% 
% index_P_SVC_max = find(max(SVC_Pressure) == SVC_Pressure); 
% time_max = time_svc(index_P_SVC_max); 
% P_SVC_max = SVC_Pressure(index_P_SVC_max); 
% 
% strminsvc = ['Minimum = ',num2str(P_SVC_min)]; 
% text(time_min,P_SVC_min,strminsvc,'HorizontalAlignment','left'); 
% 




% Comparing the values of the IVC and SVC Pressure Profiles 
figure(2) 
plot(time_ivc,IVC_Pressure,'r',time_svc,SVC_Pressure,'r--'); 
title('\fontsize{16} Regurgitant vs Ventricularized Pressure Profiles',... 
    'fontname','Times New Roman'); 
 
% Find Min and Max Regurgitant 
index_P_IVC_min = find(min(IVC_Pressure) == IVC_Pressure); 
time_min = time_ivc(index_P_IVC_min); 
P_IVC_min = IVC_Pressure(index_P_IVC_min); 
 
index_P_IVC_max = find(max(IVC_Pressure) == IVC_Pressure); 
time_max = time_ivc(index_P_IVC_max); 
P_IVC_max = IVC_Pressure(index_P_IVC_max); 
 
index_P_SVC_min = find(min(SVC_Pressure) == SVC_Pressure); 
time_min = time_svc(index_P_SVC_min); 
P_SVC_min = SVC_Pressure(index_P_SVC_min); 
 
index_P_SVC_max = find(max(SVC_Pressure) == SVC_Pressure); 
time_max = time_svc(index_P_SVC_max); 
P_SVC_max = SVC_Pressure(index_P_SVC_max); 
 
% Find Min and Max Ventricularization 
index_P_V_IVC_min = find(min(V_IVC_Pressure) == V_IVC_Pressure); 
V_time_min = time_V_ivc(index_P_V_IVC_min); 
P_V_IVC_min = V_IVC_Pressure(index_P_V_IVC_min); 
 
index_P_V_IVC_max = find(max(V_IVC_Pressure) == V_IVC_Pressure); 
V_time_max = time_V_ivc(index_P_V_IVC_max); 
P_V_IVC_max = V_IVC_Pressure(index_P_V_IVC_max); 
 index_P_V_SVC_min = find(min(V_SVC_Pressure) == V_SVC_Pressure); 
V_time_min = time_V_svc(index_P_V_SVC_min); 
P_V_SVC_min = V_SVC_Pressure(index_P_V_SVC_min); 
 
index_P_V_SVC_max = find(max(V_SVC_Pressure) == V_SVC_Pressure); 
V_time_max = time_V_svc(index_P_V_SVC_max); 
P_V_SVC_max = V_SVC_Pressure(index_P_V_SVC_max); 
 
% Plotting the texts for Regurgitation 



















% Plotting the texts for Ventricularization 
















xlabel('\fontsize{14} Seconds [s]','fontname','Times New Roman'); 
ylabel('\fontsize{14} Pressure [mmHg]','fontname','Times New Roman'); 
legend('IVC Regur','SVC Regur','IVC Ventr','SVC Ventr','location','best'); 
hold off; 
 One Cycle with Echocardiographic Time ppoints 
% x-axis 
t_ivc_onecycle = (0.01:0.01:1); 
t_ivc_V_onecycle = (0.01:0.01:1); 
 
t_svc_onecycle = (0.01:0.01:1); 




ivc = zeros(100,1); 
v_ivc = zeros(100,1); 
svc = zeros(100,1); 
v_svc = zeros(100,1); 
 
c = 1; 
for c = 1:100 
    ivc(c,1) = IVC_Pressure(c,1); 
    v_ivc(c,1) = V_IVC_Pressure(c,1); 
    svc(c,1) = SVC_Pressure(c,1); 
    v_svc(c,1) = V_SVC_Pressure(c,1); 
    c+1; 
end 
% Plot of one cycle of each waveform 
figure (3); 
plot(t_ivc_onecycle,ivc,'r',t_svc_onecycle,svc,'r--'); 
title('\fontsize{16} Regurgitant Pressure Profiles Over One Second',... 
    'fontname','Times New Roman'); 
xlabel('\fontsize{14} Seconds [s]','fontname','Times New Roman'); 
ylabel('\fontsize{14} Pressure [mmHg]','fontname','Times New Roman'); 




title('\fontsize{16} Ventricularized Pressure Profiles Over One Cycle',... 
    'fontname','Times New Roman'); 
xlabel('\fontsize{14} Seconds [s]','fontname','Times New Roman'); 
ylabel('\fontsize{14} Pressure [mmHg]','fontname','Times New Roman'); 
legend('IVC Ventricularized','SVC Ventricularized','location','best'); 
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